- ►nih.gov RK Semple, VKK Chatterjee, SO'Rahilly - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig The nuclear receptor family of PPARs was named for the ability of the original
member to induce hepatic peroxisome proliferation in mice in response to
xenobiotic stimuli. However, studies on the action and structure of the 3 ... Cited by 243 - Related articles - BL Direct - All 10 versions
BL Urquhart, RG Tirona, RB Kim - The Journal of Clinical Pharmacology, 2007 - jclinpharm.highwire.org Erratic or unpredictable response to drugs remains a challenge of modern drug
therapy. An important determinant of such interindividual differences in drug
response is variability in the expression of drug-metabolizing enzymes ... Cited by 59 - Related articles - BL Direct - All 6 versions
RL Pollex, RA Hegele - Nature Clinical Practice Cardiovascular Medicine, 2006 - nature.com Robert A Hegele is a professor of medicine and biochemistry at the Schulich
School of Medicine and Dentistry, University of Western Ontario, London, ON,
Canada, and is the Director of the Blackburn Cardiovascular Genetics ... Cited by 38 - Related articles - All 3 versions
C Phillips, J Lopez-Miranda, F Perez- … - Current Opinion in Cardiology, 2006 - journals.lww.com Purpose of review: The metabolic syndrome is a very common condition that is
associated with an increased risk of type 2 diabetes mellitus and cardiovascular
disease. The diverse clinical characteristics illustrate the complexity of ... Cited by 39 - Related articles - BL Direct - All 3 versions
RK Semple, VKK Chatterjee, SO'Rahilly - 临床调查学报, 2006 - journal.shouxi.net The nuclear receptor family of PPARs was named for the ability of the original
member to induce hepatic peroxisome proliferation in mice in response to
xenobiotic stimuli. However, studies on the action and structure of the 3 ... Cited by 37 - Related articles - Cached - All 2 versions
Y Yamada, K Kato, T Hibino, K Yokoi, H … - Atherosclerosis, 2007 - Elsevier The study population comprised 1788 unrelated Japanese individuals (1033 men,
755 women), including 1017 subjects with metabolic syndrome (634 men, 383 women)
and 771 controls (399 men, 372 women). The genotypes for 158 polymorphisms ... Cited by 30 - Related articles - All 21 versions
- ►onlinejacc.org AJ Gilde, JC Fruchart, B Staels - Journal of the American College of Cardiology, 2006 - Elsevier Since their discovery in the early 1990s, the members of the peroxisome
proliferator-activated receptor (PPAR) subfamily of nuclear receptors have been
recognized as therapeutic targets against dyslipidemia and diabetes. Recent ... Cited by 21 - Related articles - BL Direct - All 21 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by
thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPAR / agonists
(pargluva, ragaglitazar) is a widely used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
M Terán-García, C Bouchard - Applied Physiology, Nutrition, and Metabolism, 2007 - article.pubs.nrc-cnrc.gc.ca Abstract: The concept of a metabolic syndrome (MetS), a cluster of pre-clinical
metabolic alterations commonly associ- ated with obesity, is the object of much
debate. Genetic studies have the potential to contribute to some of the key ... Cited by 17 - Related articles - BL Direct - All 5 versions
JR Colca, RF Kletzien - Expert Opin. Investig. Drugs, 2006 - informahealthcare.com The ability to improve insulin sensitivity with synthetic compounds was
uncovered by empirical discoveries by Takeda in the late 1970s. The potential of
a class of thiazolidinediones for the treatment of Type 2 diabetes, by ... Cited by 13 - Related articles - BL Direct - All 5 versions
